Back to Press Release List

Advanced Renal Technologies Receives Additional U.S. Patent
Covering Citric Acid Dialysate Concentrate

August 27, 2003

BELLEVUE, Wash. – Advanced Renal Technologies (ART), a Bellevue, Washington-based medical products company, announced today that it has been granted U.S. Patent No. 6,610,206 by the U.S. Patent and Trademark Office. This patent provides ART additional protection for its unique citric acid dialysate concentrates used for hemodialysis treatment of kidney failure patients. The concentrates, previously approved by the FDA, are currently marketed under the registered trademarks Citrasate® and DRYalysate®.

ART’s unique concentrate formulations represent the most significant change in dialysate in 30 years. Citric acid, a known anticoagulant, adds anti-clotting attributes to the dialysate. Having a dialysate with anticoagulant properties is better for patients because it keeps the blood filter cleaner during the treatment. ART’s citric-acid based dialysates are well received by dialysis staff because no added steps or special training are needed to use it.

“We are pleased to be granted this latest patent because it represents a significant addition to our intellectual property portfolio,” said Mike Fulton, ART’s managing director. “ART now has enhanced patent protection through 2017 for our Citrasate® and DRYalysate® products which are gaining significant attention in the medical community. Our U.S. and foreign patents provide ART with the exclusive opportunity to continue to develop a worldwide market for our hemodialysis products.”

Advanced Renal Technologies, Inc. is a privately held company focused on the development of products to improve the treatment of patients with acute and chronic kidney failure. More information about Advanced Renal Technologies, Inc. and its dialysate products may be found at www.citrasate.com.